These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38933256)

  • 21. Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol.
    Sprague SM; Lerma E; McCormmick D; Abraham M; Batlle D
    Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S51-6. PubMed ID: 11689388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the effects of novel vitamin D receptor analog VS-105 and paricalcitol on chronic kidney disease-mineral bone disorder in an experimental model of chronic kidney disease.
    Fujii H; Yonekura Y; Nakai K; Kono K; Goto S; Nishi S
    J Steroid Biochem Mol Biol; 2017 Mar; 167():55-60. PubMed ID: 27818277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Calcium balance during calcitriol and paricalcitol administration in healthy humans.
    Hafner V; Rutsch C; Ding R; Heinrich T; Diedrichs L; Schmidt-Gayk H; Walter-Sack I; Bommer J; Mikus G
    Int J Clin Pharmacol Ther; 2008 Mar; 46(3):131-5. PubMed ID: 18397683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparative analysis of the efficacy and safety of paricalcitol versus other vitamin D receptor activators in patients undergoing hemodialysis: A systematic review and meta-analysis of 15 randomized controlled trials.
    Geng X; Shi E; Wang S; Song Y
    PLoS One; 2020; 15(5):e0233705. PubMed ID: 32470067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients.
    Lund RJ; Andress DL; Amdahl M; Williams LA; Heaney RP
    Am J Nephrol; 2010; 31(2):165-70. PubMed ID: 20016142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis.
    Martin KJ; González EA; Gellens M; Hamm LL; Abboud H; Lindberg J
    J Am Soc Nephrol; 1998 Aug; 9(8):1427-32. PubMed ID: 9697664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of paricalcitol on urinary calcium in patients with chronic kidney disease stages 2 - 4.
    Martinez-Fernandez I; Saracho R
    Clin Nephrol; 2015 Apr; 83(4):201-7. PubMed ID: 25707454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
    Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA
    Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Switch from calcitriol to paricalcitol in secondary hyperparathyroidism of hemodialysis patients: Responsiveness is related to parathyroid gland size.
    Vulpio C; Maresca G; Distasio E; Cacaci S; Panocchia N; Luciani G; Bossola M
    Hemodial Int; 2011 Jan; 15(1):69-78. PubMed ID: 21223484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study.
    Tonbul HZ; Solak Y; Atalay H; Turkmen K; Altintepe L
    Ren Fail; 2012; 34(3):297-303. PubMed ID: 22251408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of the vitamin D analogues paricalcitol and calcitriol on bone mineral in vitro.
    Balint E; Marshall CF; Sprague SM
    Am J Kidney Dis; 2000 Oct; 36(4):789-96. PubMed ID: 11007682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of the administration of different forms of vitamin D on central blood pressure and aortic stiffness, and its implication in the reduction of albuminuria in chronic kidney disease.
    Martin-Romero A; Perelló-Martínez J; Hidalgo-Santiago JC; Michan-Doña A; Bosco López Sáez J; Gómez-Fernández P
    Clin Investig Arterioscler; 2022; 34(6):311-321. PubMed ID: 35817704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interventions for metabolic bone disease in children with chronic kidney disease.
    Hahn D; Hodson EM; Craig JC
    Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD008327. PubMed ID: 26561037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vitamin D analogues for the management of secondary hyperparathyroidism.
    Martin KJ; González EA
    Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S34-40. PubMed ID: 11689385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO study.
    Roggeri DP; Mazzaferro S; Brancaccio D; Cannella G; Messa P; Di Luca M; Morosetti M; Costanzo AM; di Luzio Paparatti U; Cornago D; Cozzolino M;
    J Med Econ; 2012; 15(6):1110-7. PubMed ID: 22702445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomised clinical study of alfacalcidol and paricalcitol.
    Hansen D
    Dan Med J; 2012 Feb; 59(2):B4400. PubMed ID: 22293059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism.
    Ong LM; Narayanan P; Goh HK; Manocha AB; Ghazali A; Omar M; Mohamad S; Goh BL; Shah S; Seman MR; Vaithilingam I; Ghazalli R; Rahmat K; Shaariah W; Ching CH;
    Nephrology (Carlton); 2013 Mar; 18(3):194-200. PubMed ID: 23311404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD.
    Coyne DW; Goldberg S; Faber M; Ghossein C; Sprague SM
    Clin J Am Soc Nephrol; 2014 Sep; 9(9):1620-6. PubMed ID: 24970869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: the FARO-2 study.
    Roggeri DP; Cozzolino M; Mazzaferro S; Brancaccio D; Paoletti E; Roggeri A; Costanzo AM; di Luzio Paparatti U; Festa V; Messa P
    Int J Nephrol Renovasc Dis; 2015; 8():1-6. PubMed ID: 25565880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.